Technology Media and Telecom

Chinese company sues Texas power operator for blocking investment approved by CFIUS; China delays retirement age to relieve pressure on pensions; and China proposes identification and labeling requirements for AI-generated content

China allows fully foreign-owned hospitals and foreign investment in gene technologies; China is assessing the compatibility of the international AI agreement with its own strategic plans; and China's Ministry of Finance strengthens its regulation of foreign accounting organizations, particularly for those that do not have offices in China

Chinese court rules against international hotel brand for misuse of cross-border personal data; EU and China establish mechanism to address difficulties in data transfers; and High-frequency futures traders question their survival in an increasingly hostile Chinese futures market

U.S. lawmakers call on the government to scrutinize drugmakers' clinical trials in China; China removes restrictions for foreign investments in the manufacturing and services industries; and Cross-Boundary Wealth Connect gains 10 new additional securities firms for increased offshore investment opportunities.

Export pharmaceuticals commissioned for production from a foreign pharmaceutical manufacturer may not be sold and used in the PRC

New rules applicable to Shanghai's Lin-Gang New Area have been released. Wenpei Yu and Yunsi Hu of Lifeng Partners analyze their workings, how they fit into China's existing system of cross-border data transfer rules and why they are so significant for biomedical companies operating in the zone

Nasdaq questioned the identities and backgrounds of Chinese IPO investors; China rolls out new phase of Golden Tax System; and U.S. Congress attempts to prevent Chinese companies from using de minimis loophole to avoid tariffs

U.S. plans to restrict Chinese software in electric and internet-connected cars; China increases control over offshore capital flows; and Chinese firms plan to expand into the U.S. Midwest but have regulatory concerns.

Revised Chinese Company Law requires mandatory worker representation in boardrooms; Shanghai's biomedical measures catch the most attention; and Merchants of Pinduoduo's international arm, Temu, struggle to sue the company due to its complex structure.